SCHEMBL1565536

SCHEMBL1565536

O=C(Nc1nccs1)C(Oc1ccc(Cl)c(Cl)c1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.56
▸ MAPT P10636 1/20 0.54
▸ FFAR2 O15552 8/20 0.53
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ PIK3CD O00329 1/20 0.49
▸ PIK3C2B O00750 1/20 0.49
▸ AURKA O14965 1/20 0.49
▸ PIK3C2G O75747 1/20 0.49
▸ CDK1 P06493 1/20 0.49
▸ CDK4 P11802 1/20 0.49
▸ CCND1 P24385 1/20 0.49
▸ CDK2 P24941 1/20 0.49
▸ MAPK3 P27361 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ CCND3 P30281 1/20 0.49
▸ MAPK4 P31152 1/20 0.49
▸ PIK3CA P42336 1/20 0.49
▸ PIK3CB P42338 1/20 0.49
▸ PIK3CG P48736 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652833 0.81 GCK (0.56) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL2652760 0.80 GCK (0.55) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL1564970 0.80 LMNA (0.57) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL1565145 0.79 LMNA (0.66) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL1564845 0.79 LMNA (0.69) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL1565596 0.79 LMNA (0.66) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL1565489 0.79 LMNA (0.56) LMNAFFAR2MEN1KMT2AXBP1
SCHEMBL1565420 0.79 NPC1 (0.60) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL2652722 0.79 GCK (0.68) LMNAMAPTFFAR2MEN1KMT2A
SCHEMBL1565765 0.78 LMNA (0.53) LMNAMAPTFFAR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US claimed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-1458382-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171411-A1 Amide derivatives as therapeutic agents GK, GCKR, GCK LMNA 3743/4885MAPT 4194/4885FFAR2 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback